Abstract
As personal genomics moves into the clinical sphere, healthcare providers face the daunting task of interpreting thousands of genetic variants. This paper proposes a framework that treats individual genetic variants as standard diagnostic tests. By applying Likelihood Ratios (LRs) from Evidence-Based Medicine (EBM), clinicians can mathematically combine a patient’s baseline risk with their genetic data to calculate a concrete "post-test probability" of disease, bridging the gap between complex research and actionable bedside medicine.
The Challenge of the "Genomic Deluge"
Direct-to-consumer genotyping and whole-genome sequencing have created a "genomic deluge"—thousands of single nucleotide polymorphisms (SNPs) linked to various diseases. For clinicians, this presents a significant challenge: the literature is often contradictory, and research typically reports "Odds Ratios," which are difficult to apply to an individual without knowing their baseline risk. Furthermore, testing healthy individuals for thousands of rare diseases risks the "incidentalome" problem, where "high-risk" markers may simply be false positives in a clinical context.
Methodology: Genomics as a Lab Panel
The proposed solution involves adopting the well-established Bayesian framework of Evidence-Based Medicine. By shifting the view of the genome from a mysterious blueprint to a massive panel of individual lab tests, the data becomes manageable for doctors trained in classical diagnostics.
Likelihood Ratios and the Fagan Nomogram
Instead of general risk, the authors define the Likelihood Ratio (LR) for a specific genotype as the probability of having that genotype if the disease is present, divided by the probability of having it if it is not. Each SNP is treated as an independent laboratory test. Because these are statistically independent, they can be "chained" by multiplying their LRs together:
$$\text{Pre-test Odds} \times LR_1 \times LR_2 \dots \times LR_n = \text{Post-test Odds}$$
To simplify this for clinical use, the authors advocate for the Fagan Nomogram, a graphical tool that allows clinicians to visually map how a genetic test result shifts a patient's probability of disease.
Quantifying Clinical Impact
To demonstrate feasibility, the authors curated a dataset of 2,092 disease-variant associations from 2,174 articles. Their analysis highlights the critical role of pre-test probability. For example, if a disease is extremely rare (e.g., 0.01% prevalence), even a "strong" genetic marker with an LR of 5 only raises the patient's risk to 0.05%, remaining clinically irrelevant.
The following table illustrates how different strengths of genetic associations and disease types affect the final risk assessment:
Limitations and the Path Forward
While this framework provides a robust approximation for clinical use, several challenges remain. "Missing heritability" means common SNPs only explain a fraction of disease risk. Additionally, Linkage Disequilibrium (LD)—where SNPs are inherited together—requires more complex models to avoid "double-counting" risk.
The authors also highlight a significant reporting gap: only 46% of surveyed publications provided enough data to calculate an LR. They call for improved reporting standards, such as STREGA, to ensure genomic research becomes "clinically readable" and useful for evidence-based practice.
Summary updated